{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Astragalus membranaceus (Fisch.) Bge (AM)", "Bacillus subtilis", "Coriolus versicolor (CV)", "SARS-CoV-2", "cytokines", "dendritic cells", "macrophages"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37446658", "DateCompleted": {"Year": "2023", "Month": "07", "Day": "17"}, "DateRevised": {"Year": "2023", "Month": "07", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "06", "Day": "26"}], "Language": ["eng"], "ELocationID": ["4996", "10.3390/molecules28134996"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "13", "PubDate": {"Year": "2023", "Month": "Jun", "Day": "26"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Creating a Vaccine-like Supplement against Respiratory Infection Using Recombinant <i>Bacillus subtilis</i> Spores Expressing SARS-CoV-2 Spike Protein with Natural Products.", "Abstract": {"AbstractText": ["Vaccination is the most effective method of combating COVID-19 infection, but people with a psychological fear of needles and side effects are hesitant to receive the current vaccination, and alternative delivery methods may help. <i>Bacillus subtilis</i>, a harmless intestinal commensal, has recently earned a strong reputation as a vaccine production host and delivery vector, with advantages such as low cost, safety for human consumption, and straightforward oral administration. In this study, we have succeeded generating \"S spores\" by engineering <i>B. subtilis</i> with spore coat proteins resembling the spike (S) protein of the ancestral SARS-CoV-2 coronavirus. With the addition of two immunostimulating natural products as adjuvants, namely <i>Astragalus membranaceus</i> (Fisch.) Bge (AM) and <i>Coriolus versicolor</i> (CV), oral administration of S spores could elicit mild immune responses against COVID-19 infection without toxicity. Mucosal IgA against the S protein was enhanced by co-feeding with AM and CV in an S spores-inoculated mouse model. Faster and stronger IgG responses against the S protein were observed when the mice were fed with S spores prior to vaccination with the commercial COVID-19 vaccine CoronaVac. In vitro studies demonstrated that AM, CV, and <i>B. subtilis</i> spores could dose-dependently activate both macrophages and dendritic cells by secreting innate immunity-related IL-1\u03b2, IL-6, and TNF-\u03b1, and some other proinflammatory chemokines and cytokines. In conclusion, the combination of S spores with AM and CV may be helpful in developing a vaccine-like supplement against respiratory infection."]}, "AuthorList": [{"Identifier": ["0000-0001-5505-1065"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Chan", "ForeName": "Ben Chung-Lap", "Initials": "BC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Li", "ForeName": "Peiting", "Initials": "P"}, {"Identifier": ["0000-0003-2416-0714"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, STEM College, RMIT University, Bundoora, VIC 3083, Australia."}], "LastName": "Tsang", "ForeName": "Miranda Sin-Man", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Department, DreamTec Cytokines Limited, Hong Kong, China."}], "LastName": "Sung", "ForeName": "Johnny Chun-Chau", "Initials": "JC"}, {"Identifier": ["0000-0001-5229-0124"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Department, DreamTec Cytokines Limited, Hong Kong, China."}], "LastName": "Kwong", "ForeName": "Keith Wai-Yeung", "Initials": "KW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Zheng", "ForeName": "Tao", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China."}], "LastName": "Hon", "ForeName": "Sharon Sze-Man", "Initials": "SS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Lau", "ForeName": "Ching-Po", "Initials": "CP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Cheng", "ForeName": "Wen", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Chen", "ForeName": "Fang", "Initials": "F"}, {"Identifier": ["0000-0002-7409-1270"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Lau", "ForeName": "Clara Bik-San", "Initials": "CB"}, {"Identifier": ["0000-0002-0195-4688"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Leung", "ForeName": "Ping-Chung", "Initials": "PC"}, {"Identifier": ["0000-0002-5637-8331"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Wong", "ForeName": "Chun-Kwok", "Initials": "CK"}], "GrantList": [{"GrantID": "PRP/008/21FX", "Agency": "Innovation and Technology Commission", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "sinovac COVID-19 vaccine"}, {"RegistryNumber": "0", "NameOfSubstance": "COVID-19 Vaccines"}, {"RegistryNumber": "0", "NameOfSubstance": "spike protein, SARS-CoV-2"}, {"RegistryNumber": "0", "NameOfSubstance": "Spike Glycoprotein, Coronavirus"}, {"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Vaccines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "COVID-19 Vaccines"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Spike Glycoprotein, Coronavirus"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Bacillus subtilis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Biological Products"}, {"QualifierName": ["metabolism"], "DescriptorName": "Spores, Bacterial"}, {"QualifierName": ["prevention & control", "metabolism"], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Vaccines"}, {"QualifierName": [], "DescriptorName": "Immunity, Innate"}], "CoiStatement": "The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Callaway E. COVID \u2018variant soup\u2019 is making winter surges hard to predict. Nature. 2022;611:213\u2013214. doi: 10.1038/d41586-022-03445-6.", "ArticleIdList": ["10.1038/d41586-022-03445-6", "36307585"]}, {"Citation": "Wang Q., Iketani S., Li Z., Liu L., Guo Y., Huang Y., Bowen A.D., Liu M., Wang M., Yu J., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279\u2013286. doi: 10.1016/j.cell.2022.12.018.", "ArticleIdList": ["10.1016/j.cell.2022.12.018", "PMC9747694", "36580913"]}, {"Citation": "Hachmann N.P., Miller J., Collier A.Y., Ventura J.D., Yu J., Rowe M., Bondzie E.A., Powers O., Surve N., Hall K., et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 2022;387:86\u201388. doi: 10.1056/NEJMc2206576.", "ArticleIdList": ["10.1056/NEJMc2206576", "PMC9258748", "35731894"]}, {"Citation": "Qu P., Faraone J., Evans J.P., Zou X., Zheng Y.M., Carlin C., Bednash J.S., Lozanski G., Mallampalli R.K., Saif L.J., et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N. Engl. J. Med. 2022;386:2526\u20132528. doi: 10.1056/NEJMc2206725.", "ArticleIdList": ["10.1056/NEJMc2206725", "PMC9258774", "35704428"]}, {"Citation": "Fonager J., Bennedbaek M., Bager P., Wohlfahrt J., Ellegaard K.M., Ingham A.C., Edslev S.M., Stegger M., Sieber R.N., Lassauniere R., et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Eurosurveillance. 2022;27:2200181. doi: 10.2807/1560-7917.ES.2022.27.10.2200181.", "ArticleIdList": ["10.2807/1560-7917.ES.2022.27.10.2200181", "PMC8915403", "35272746"]}, {"Citation": "Barnes A.G., Cerovic V., Hobson P.S., Klavinskis L.S. Bacillus subtilis spores: A novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur. J. Immunol. 2007;37:1538\u20131547. doi: 10.1002/eji.200636875.", "ArticleIdList": ["10.1002/eji.200636875", "17474150"]}, {"Citation": "de Souza R.D., Batista M.T., Luiz W.B., Cavalcante R.C.M., Amorim J.H., Bizerra R.S.P., Martins E.G., Ferreira L.C.D. Bacillus subtilis Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action. PLoS ONE. 2014;9:e87454. doi: 10.1371/journal.pone.0087454.", "ArticleIdList": ["10.1371/journal.pone.0087454", "PMC3903701", "24475289"]}, {"Citation": "Tavares Batista M., Souza R.D., Paccez J.D., Luiz W.B., Ferreira E.L., Cavalcante R.C., Ferreira R.C., Ferreira L.C. Gut adhesive Bacillus subtilis spores as a platform for mucosal delivery of antigens. Infect. Immun. 2014;82:1414\u20131423. doi: 10.1128/IAI.01255-13.", "ArticleIdList": ["10.1128/IAI.01255-13", "PMC3993416", "24421038"]}, {"Citation": "Sung J.C., Lai N.C., Wu K.C., Choi M.C., Ma C.H., Lin J., Kuok C.N., Leong W.L., Lam W.K., Hamied Y.K., et al. Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines. Vaccines. 2022;10:1014. doi: 10.3390/vaccines10071014.", "ArticleIdList": ["10.3390/vaccines10071014", "PMC9322707", "35891178"]}, {"Citation": "Vetrakova A., Chovanova R.K., Rechtorikova R., Krajcikova D., Barak I. Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein. Comput. Struct. Biotechnol. J. 2023;21:1550\u20131556. doi: 10.1016/j.csbj.2023.02.007.", "ArticleIdList": ["10.1016/j.csbj.2023.02.007", "PMC9904849", "36778063"]}, {"Citation": "Hong F., Xiao W., Ragupathi G., Lau C.B., Leung P.C., Yeung K.S., George C., Cassileth B., Kennelly E., Livingston P.O. The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines. Planta Med. 2011;77:817\u2013824. doi: 10.1055/s-0030-1250574.", "ArticleIdList": ["10.1055/s-0030-1250574", "PMC3711077", "21128203"]}, {"Citation": "Ragupathi G., Yeung K.S., Leung P.C., Lee M., Lau C.B., Vickers A., Hood C., Deng G., Cheung N.K., Cassileth B., et al. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine. 2008;26:4860\u20134865. doi: 10.1016/j.vaccine.2008.06.098.", "ArticleIdList": ["10.1016/j.vaccine.2008.06.098", "PMC2565601", "18640165"]}, {"Citation": "Eliza W.L.Y., Fai C.K., Chung L.P. Efficacy of Yun Zhi (Coriolus versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis. Recent Pat. Inflamm. Allergy Drug Discov. 2012;6:78\u201387. doi: 10.2174/187221312798889310.", "ArticleIdList": ["10.2174/187221312798889310", "22185453"]}, {"Citation": "Yin J.Y., Chan B.C.L., Yu H., Lau I.Y.K., Han X.Q., Cheng S.W., Wong C.K., Lau C.B.S., Xie M.Y., Fung K.P., et al. Separation, structure characterization, conformation and immunomodulating effect of a hyperbranched heteroglycan from Radix Astragali. Carbohydr. Polym. 2012;87:667\u2013675.", "ArticleIdList": ["34663019"]}, {"Citation": "Han X.Q., Chung Lap Chan B., Dong C.X., Yang Y.H., Ko C.H., Gar-Lee Yue G., Chen D., Wong C.K., Bik-San Lau C., Tu P.F., et al. Isolation, structure characterization, and immunomodulating activity of a hyperbranched polysaccharide from the fruiting bodies of Ganoderma sinense. J. Agric. Food Chem. 2012;60:4276\u20134281. doi: 10.1021/jf205056u.", "ArticleIdList": ["10.1021/jf205056u", "22500548"]}, {"Citation": "Han X.Q., Chan B.C., Yu H., Yang Y.H., Hu S.Q., Ko C.H., Dong C.X., Wong C.K., Shaw P.C., Fung K.P., et al. Structural characterization and immuno-modulating activities of a polysaccharide from Ganoderma sinense. Int. J. Biol. Macromol. 2012;51:597\u2013603. doi: 10.1016/j.ijbiomac.2012.06.029.", "ArticleIdList": ["10.1016/j.ijbiomac.2012.06.029", "22750578"]}, {"Citation": "Han X.Q., Yue G.L., Yue R.Q., Dong C.X., Chan C.L., Ko C.H., Cheung W.S., Luo K.W., Dai H., Wong C.K., et al. Structure elucidation and immunomodulatory activity of a beta glucan from the fruiting bodies of Ganoderma sinense. PLoS ONE. 2014;9:e100380.", "ArticleIdList": ["PMC4094382", "25014571"]}, {"Citation": "Topfer E., Boraschi D., Italiani P. Innate Immune Memory: The Latest Frontier of Adjuvanticity. J. Immunol. Res. 2015;2015:478408. doi: 10.1155/2015/478408.", "ArticleIdList": ["10.1155/2015/478408", "PMC4561982", "26380322"]}, {"Citation": "Zhou Z., Dong H., Huang Y., Yao S., Liang B., Xie Y., Long Y., Mai J., Gong S. Recombinant Bacillus subtilis spores expressing cholera toxin B subunit and Helicobacter pylori urease B confer protection against H. pylori in mice. J. Med. Microbiol. 2017;66:83\u201389. doi: 10.1099/jmm.0.000404.", "ArticleIdList": ["10.1099/jmm.0.000404", "27930268"]}, {"Citation": "Potocki W., Negri A., Peszynska-Sularz G., Hinc K., Obuchowski M., Iwanicki A. IL-1 Fragment Modulates Immune Response Elicited by Recombinant Bacillus subtilis Spores Presenting an Antigen/Adjuvant Chimeric Protein. Mol. Biotechnol. 2018;60:810\u2013819. doi: 10.1007/s12033-018-0117-0.", "ArticleIdList": ["10.1007/s12033-018-0117-0", "PMC6182635", "30178298"]}, {"Citation": "Knoll R., Schultze J.L., Schulte-Schrepping J. Monocytes and Macrophages in COVID-19. Front. Immunol. 2021;12:720109.", "ArticleIdList": ["PMC8335157", "34367190"]}, {"Citation": "van der Meer J.W.M., Joosten L.A.B., Riksen N., Netea M.G. Trained immunity: A smart way to enhance innate immune defence. Mol. Immunol. 2015;68:40\u201344.", "ArticleIdList": ["26597205"]}, {"Citation": "Gyssens I.C., Netea M.G. Heterologous effects of vaccination and trained immunity. Clin. Microbiol. Infect. 2019;25:1457\u20131458.", "ArticleIdList": ["31158520"]}, {"Citation": "Jensen J., Warner T., Balish E. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: Role of polymorphonuclear leukocytes and macrophages. J. Infect. Dis. 1993;167:912\u2013919. doi: 10.1093/infdis/167.4.912.", "ArticleIdList": ["10.1093/infdis/167.4.912", "8383723"]}, {"Citation": "Cirovic B., de Bree L.C.J., Groh L., Blok B.A., Chan J., van der Velden W., Bremmers M.E.J., van Crevel R., Handler K., Picelli S., et al. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. Cell Host Microbe. 2020;28:322\u2013334.", "ArticleIdList": ["PMC7295478", "32544459"]}, {"Citation": "Perez-Hernandez C.A., Kern C.C., Butkeviciute E., McCarthy E., Dockrell H.M., Moreno-Altamirano M.M.B., Aguilar-Lopez B.A., Bhosale G., Wang H., Gems D., et al. Mitochondrial Signature in Human Monocytes and Resistance to Infection in C. elegans During Fumarate-Induced Innate Immune Training. Front. Immunol. 2020;11:1715. doi: 10.3389/fimmu.2020.01715.", "ArticleIdList": ["10.3389/fimmu.2020.01715", "PMC7419614", "32849605"]}, {"Citation": "Pellon A., Nasab S.D.S., Moyes D.L. New Insights in Candida albicans Innate Immunity at the Mucosa: Toxins, Epithelium, Metabolism, and Beyond. Front. Cell. Infect. Microbiol. 2020;10:81.", "ArticleIdList": ["PMC7062647", "32195196"]}, {"Citation": "Wang X., Guan F., Miller H., Byazrova M.G., Cndotti F., Benlagha K., Camara N.O.S., Lei J., Filatov A., Liu C. The role of dendritic cells in COVID-19 infection. Emerg. Microbes Infect. 2023;12:2195019. doi: 10.1080/22221751.2023.2195019.", "ArticleIdList": ["10.1080/22221751.2023.2195019", "PMC10171120", "36946172"]}, {"Citation": "Netea M.G., Dominguez-Andres J., Barreiro L.B., Chavakis T., Divangahi M., Fuchs E., Joosten L.A.B., van der Meer J.W.M., Mhlanga M.M., Mulder W.J.M., et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 2020;20:375\u2013388.", "ArticleIdList": ["PMC7186935", "32132681"]}, {"Citation": "Mou C., Zhu L., Xing X., Lin J., Yang Q. Immune responses induced by recombinant Bacillus subtilis expressing the spike protein of transmissible gastroenteritis virus in pigs. Antivir. Res. 2016;131:74\u201384.", "ArticleIdList": ["26988122"]}, {"Citation": "Hu B., Li C., Lu H., Zhu Z., Du S., Ye M., Tan L., Ren D., Han J., Kan S., et al. Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit. J. Virol. Methods. 2011;171:272\u2013279. doi: 10.1016/j.jviromet.2010.11.023.", "ArticleIdList": ["10.1016/j.jviromet.2010.11.023", "21129406"]}, {"Citation": "Wang Y., Miao Y., Hu L.P., Kai W., Zhu R. Immunization of mice against alpha, beta, and epsilon toxins of Clostridium perfringens using recombinant rCpa-b-x expressed by Bacillus subtilis. Mol. Immunol. 2020;123:88\u201396.", "ArticleIdList": ["32447084"]}, {"Citation": "Jiang B., Li Z., Ou B., Duan Q., Zhu G. Targeting ideal oral vaccine vectors based on probiotics: A systematical view. Appl. Microbiol. Biotechnol. 2019;103:3941\u20133953.", "ArticleIdList": ["30915504"]}, {"Citation": "Lei Z., Zhu L., Pan P., Ruan Z., Gu Y., Xia X., Wang S., Ge W., Yao Y., Luo F., et al. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. J. Med. Virol. 2023;95:e28475. doi: 10.1002/jmv.28475.", "ArticleIdList": ["10.1002/jmv.28475", "36606607"]}, {"Citation": "Yao Y., Liu Z.J., Zhang Y.K., Sun H.J. Mechanism and potential treatments for gastrointestinal dysfunction in patients with COVID-19. World J. Gastroenterol. 2022;28:6811\u20136826. doi: 10.3748/wjg.v28.i48.6811.", "ArticleIdList": ["10.3748/wjg.v28.i48.6811", "PMC9827583", "36632313"]}, {"Citation": "Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G.F., Tan W., Wu G., Xu M., Lou Z., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021;21:39\u201351. doi: 10.1016/S1473-3099(20)30831-8.", "ArticleIdList": ["10.1016/S1473-3099(20)30831-8", "PMC7561304", "33069281"]}, {"Citation": "Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603\u20132615.", "ArticleIdList": ["PMC7745181", "33301246"]}, {"Citation": "Rhayat L., Maresca M., Nicoletti C., Perrier J., Brinch K.S., Christian S., Devillard E., Eckhardt E. Effect of Bacillus subtilis Strains on Intestinal Barrier Function and Inflammatory Response. Front. Immunol. 2019;10:564. doi: 10.3389/fimmu.2019.00564.", "ArticleIdList": ["10.3389/fimmu.2019.00564", "PMC6449611", "30984172"]}, {"Citation": "Alam S., Sadiqi S., Sabir M., Nisa S., Ahmad S., Abbasi S.W. Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. 2022;40:5748\u20135758.", "ArticleIdList": ["PMC7814571", "33446058"]}, {"Citation": "Commercial Press . Chinese Pharmacopoeia. Commercial Press; Shanghai, China: 2015."}, {"Citation": "Tani T., Shimizu T., Tani M., Shoji H., Endo Y. Anti-endotoxin Properties of Polymyxin B-immobilized Fibers. Adv. Exp. Med. Biol. 2019;1145:321\u2013341.", "ArticleIdList": ["PMC7123644", "31364085"]}, {"Citation": "Wu Z., Hu Y., Xu M., Chen Z., Yang W., Jiang Z., Li M., Jin H., Cui G., Chen P., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:803\u2013812.", "ArticleIdList": ["PMC7906628", "33548194"]}, {"Citation": "Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K., Han W., Chen Z., Tang R., Yin W., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181\u2013192. doi: 10.1016/S1473-3099(20)30843-4.", "ArticleIdList": ["10.1016/S1473-3099(20)30843-4", "PMC7832443", "33217362"]}, {"Citation": "Peng Q., Zhou R., Wang Y., Zhao M., Liu N., Li S., Huang H., Yang D., Au K.K., Wang H., et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904.", "ArticleIdList": ["PMC8893246", "35248996"]}, {"Citation": "Ribeiro L.A., Azevedo V., Le Loir Y., Oliveira S.C., Dieye Y., Piard J.C., Gruss A., Langella P. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: A first step towards food-grade live vaccines against brucellosis. Appl. Environ. Microbiol. 2002;68:910\u2013916. doi: 10.1128/AEM.68.2.910-916.2002.", "ArticleIdList": ["10.1128/AEM.68.2.910-916.2002", "PMC126665", "11823235"]}, {"Citation": "Wang R., Sun C., Ma J., Yu C., Kong D., Chen M., Liu X., Zhao D., Gao S., Kou S., et al. A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Vaccines. 2022;10:702. doi: 10.3390/vaccines10050702.", "ArticleIdList": ["10.3390/vaccines10050702", "PMC9143086", "35632456"]}, {"Citation": "Castro J.T., Azevedo P., Fumagalli M.J., Hojo-Souza N.S., Salazar N., Almeida G.G., Oliveira L.I., Faustino L., Antonelli L.R., Marcal T.G., et al. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nat. Commun. 2022;13:4831.", "ArticleIdList": ["PMC9382605", "35977933"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "6", "Day": "2"}, {"Year": "2023", "Month": "6", "Day": "19"}, {"Year": "2023", "Month": "6", "Day": "24"}, {"Year": "2023", "Month": "7", "Day": "17", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "7", "Day": "14", "Hour": "13", "Minute": "7"}, {"Year": "2023", "Month": "7", "Day": "14", "Hour": "1", "Minute": "18"}, {"Year": "2023", "Month": "6", "Day": "26"}], "PublicationStatus": "epublish", "ArticleIdList": ["37446658", "PMC10343243", "10.3390/molecules28134996", "molecules28134996"]}}], "PubmedBookArticle": []}